Posts

MapLight shares sink on mixed Phase 2 schizophrenia readout

on

MoonLake shares crash after mixed results in pivotal hidradenitis suppurativa studies

on

Placebo Response Trips Up Harmony Biosciences’ Fragile X Drug in Late-Stage Phase 3 Trial

on

Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo

on

HHS to require all "new vaccines" to be tested against placebo

on

Transcend's neuroplastogen posts positive mid-stage results in PTSD

on

Supernus Pharmaceuticals' Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial

on

Supernus Pharmaceuticals' Stock Plummets as Phase 2b Depression Drug Trial Fails to Meet Primary Endpoint

on

AlgoTx's ATX01 Shows Promise Despite Missing Primary Endpoint in Phase 2 CIPN Trial

on